Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.03
BSX's Cash-to-Debt is ranked lower than
97% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. BSX: 0.03 )
Ranked among companies with meaningful Cash-to-Debt only.
BSX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.17 Max: N/A
Current: 0.03
Equity-to-Asset 0.39
BSX's Equity-to-Asset is ranked lower than
82% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. BSX: 0.39 )
Ranked among companies with meaningful Equity-to-Asset only.
BSX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.18  Med: 0.51 Max: 0.83
Current: 0.39
0.18
0.83
Interest Coverage 2.23
BSX's Interest Coverage is ranked lower than
93% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 86.37 vs. BSX: 2.23 )
Ranked among companies with meaningful Interest Coverage only.
BSX' s Interest Coverage Range Over the Past 10 Years
Min: 0.37  Med: 1.92 Max: 3.22
Current: 2.23
0.37
3.22
Piotroski F-Score: 6
Altman Z-Score: 1.91
Beneish M-Score: -2.54
WACC vs ROIC
7.37%
5.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 6.04
BSX's Operating Margin % is ranked higher than
58% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. BSX: 6.04 )
Ranked among companies with meaningful Operating Margin % only.
BSX' s Operating Margin % Range Over the Past 10 Years
Min: -53.36  Med: -4.23 Max: 11.86
Current: 6.04
-53.36
11.86
Net Margin % 5.07
BSX's Net Margin % is ranked higher than
59% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. BSX: 5.07 )
Ranked among companies with meaningful Net Margin % only.
BSX' s Net Margin % Range Over the Past 10 Years
Min: -56.12  Med: -4.56 Max: 5.79
Current: 5.07
-56.12
5.79
ROE % 6.60
BSX's ROE % is ranked higher than
59% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. BSX: 6.60 )
Ranked among companies with meaningful ROE % only.
BSX' s ROE % Range Over the Past 10 Years
Min: -44.65  Med: -3.5 Max: 6.6
Current: 6.6
-44.65
6.6
ROA % 2.44
BSX's ROA % is ranked higher than
57% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. BSX: 2.44 )
Ranked among companies with meaningful ROA % only.
BSX' s ROA % Range Over the Past 10 Years
Min: -21.16  Med: -1.48 Max: 2.44
Current: 2.44
-21.16
2.44
ROC (Joel Greenblatt) % 28.98
BSX's ROC (Joel Greenblatt) % is ranked higher than
72% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. BSX: 28.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BSX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -144.7  Med: -14.88 Max: 32.39
Current: 28.98
-144.7
32.39
3-Year Revenue Growth Rate 4.60
BSX's 3-Year Revenue Growth Rate is ranked higher than
51% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. BSX: 4.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BSX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.5  Med: 4.6 Max: 29
Current: 4.6
-10.5
29
3-Year EBITDA Growth Rate 14.70
BSX's 3-Year EBITDA Growth Rate is ranked higher than
58% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. BSX: 14.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BSX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -71.1  Med: 14.7 Max: 271.1
Current: 14.7
-71.1
271.1
GuruFocus has detected 2 Warning Signs with Boston Scientific Corp $BSX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BSX's 30-Y Financials

Financials (Next Earnings Date: 2017-07-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

BSX Guru Trades in Q2 2016

Paul Tudor Jones 33,994 sh (New)
Jim Simons 4,901,905 sh (+692.67%)
John Paulson 94,000 sh (+27.03%)
Eaton Vance Worldwide Health Sciences Fund 3,880,000 sh (+12.46%)
PRIMECAP Management 42,640,450 sh (-1.65%)
Dodge & Cox 384,930 sh (-9.94%)
Mario Gabelli 687,746 sh (-13.60%)
Vanguard Health Care Fund 53,619,190 sh (-15.19%)
Pioneer Investments 2,962,863 sh (-21.76%)
Steven Cohen 1,915,982 sh (-28.12%)
Michael Price 900,000 sh (-48.28%)
Ray Dalio 9,684 sh (-73.24%)
Diamond Hill Capital 4,863,821 sh (-76.09%)
» More
Q3 2016

BSX Guru Trades in Q3 2016

Ray Dalio 50,900 sh (+425.61%)
John Paulson 410,000 sh (+336.17%)
Dodge & Cox 382,130 sh (-0.73%)
PRIMECAP Management 41,805,050 sh (-1.96%)
Mario Gabelli 673,046 sh (-2.14%)
Vanguard Health Care Fund 46,520,049 sh (-13.24%)
Steven Cohen 1,622,600 sh (-15.31%)
Paul Tudor Jones 26,610 sh (-21.72%)
Michael Price 700,000 sh (-22.22%)
Diamond Hill Capital 3,289,862 sh (-32.36%)
Pioneer Investments 1,878,761 sh (-36.59%)
Jim Simons 1,884,005 sh (-61.57%)
Eaton Vance Worldwide Health Sciences Fund 1,698,025 sh (-56.24%)
» More
Q4 2016

BSX Guru Trades in Q4 2016

David Tepper 550,000 sh (New)
Joel Greenblatt 99,384 sh (New)
Ray Dalio 91,000 sh (+78.78%)
Jim Simons 2,625,305 sh (+39.35%)
Pioneer Investments 1,941,017 sh (+3.31%)
Diamond Hill Capital 3,351,408 sh (+1.87%)
PRIMECAP Management 41,920,457 sh (+0.28%)
Michael Price 700,000 sh (unchged)
Steven Cohen 500,000 sh (unchged)
Paul Tudor Jones Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
Dodge & Cox 371,671 sh (-2.74%)
Mario Gabelli 653,146 sh (-2.96%)
Vanguard Health Care Fund 43,872,669 sh (-5.69%)
John Paulson 288,000 sh (-29.76%)
Steven Cohen 358,400 sh (-77.91%)
» More
Q1 2017

BSX Guru Trades in Q1 2017

Julian Robertson 900,000 sh (New)
Caxton Associates 20,100 sh (New)
Joel Greenblatt 1,664,082 sh (+1574.40%)
David Tepper 3,340,000 sh (+507.27%)
Jim Simons 5,726,705 sh (+118.13%)
Diamond Hill Capital 3,361,258 sh (+0.29%)
Ray Dalio Sold Out
John Paulson Sold Out
Steven Cohen Sold Out
Pioneer Investments 1,938,677 sh (-0.12%)
PRIMECAP Management 41,755,967 sh (-0.39%)
Vanguard Health Care Fund 42,272,393 sh (-3.65%)
Mario Gabelli 625,559 sh (-4.22%)
Dodge & Cox 328,655 sh (-11.57%)
Michael Price 500,000 sh (-28.57%)
» More
» Details

Insider Trades

Latest Guru Trades with BSX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NAS:ISRG, NYSE:ZBH, NYSE:EW, NYSE:SYK, OTCPK:SNNUF, NAS:ALGN, OTCPK:SONVY, NYSE:TFX, NYSE:VAR, OTCPK:CNVVY, OTCPK:WILLF, OTCPK:CHEOY, NAS:ABMD, NAS:MASI, OTCPK:GGNDF, OTCPK:FSPKF, OTCPK:EKTAY, NAS:NUVA, NAS:IART, OTCPK:SHWGY » details
Traded in other countries:BSX.Germany,
Headquarter Location:USA
Boston Scientific Corp is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.

Boston Scientific produces less-invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract tests, and treatment of incontinence. The firm markets its devices to health-care professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Top Ranked Articles about Boston Scientific Corp

Julian Robertson Buys Adobe and Sells Apple in 1st Quarter Guru adds 3 positions and closes 3 others
Julian Robertson (Trades, Portfolio), founder of Tiger Management, invests with long-short strategies. During the first quarter, the guru added positions in Adobe Systems Inc. (NASDAQ:ADBE), Boston Scientific Corp. (NYSE:BSX) and JPMorgan Chase & Co. (NYSE:JPM). On the sell side, Robertson divested his holdings in HollyFrontier Corp. (NYSE:HFC), Apple Inc. (NASDAQ:AAPL) and Shire PLC (NASDAQ:SHPG). Read more...
Diamond Hill Buys Ford, Sells Boston Scientific Firm's largest 2nd quarter trades
Diamond Hill Capital (Trades, Portfolio) Management Inc. was established in 2000 and is a registered investment adviser based in Columbus, Ohio. During the second quarter, the firm traded the following stocks. Read more...
Michael Price Trims Boston Scientific, Buys Outerwall The guru's largest trades of 2nd quarter
Michael Price (Trades, Portfolio) is the 271st richest person in the world, according to Forbes. A renowned money manager, he learned finance as a $200-a-week research assistant under Max Heine. The following are his largest trades of the second quarter: Read more...
Vanguard Sold Shares in 7 of Top 10 Quarterly Transactions Guru exited position in Pfizer in 2nd quarter
Seven of Vanguard Health Care Fund (Trades, Portfolio)’s top 10 second-quarter transactions were divestitures or reductions, including its most noteworthy deal of the quarter. Read more...
Belo Sun Announces AGM Results

TORONTO, ONTARIO--(Marketwired - May 30, 2016) - Belo Sun Mining Corp. ("Belo Sun" or the "Company") (TSX:BSX) reports, in accordance with the policies of the Toronto Stock Exchange, that the nominees listed in the management proxy circular dated April 20, 2016 for the 2016 Annual Meeting of shareholders of Belo Sun (the "Meeting") were elected as directors of the Company. Shareholders at the annual meeting also approved the appointment of the Company's auditors. 79% of all of the issued and outstanding shares of Belo Sun were represented at the Meeting. Detailed results of the vote for the election of directors held at the Meeting on May 27, 2016 in Toronto, Ontario are set out below. Election of Directors The shareholders approved the election as directors of the persons listed below, based on the following vote.


Nominee

% Votes For

% Votes Withheld


Peter Tagliamonte

88.7%

11.3%


Stan Bharti

57.8%

42.2%


Mark Eaton

88.7%

11.3%


William Clarke

98.3%

1.7%


Denis Arsenault

98.5%

1.5%


Carol Fries

93.5%

6.5%



The Belo Sun board is comprised of an equal number of independent and non-independent directors. As such, proxy advisory firms, Glass Lewis & Co. and Institutional Shareholder Services, recommended that shareholders withhold their vote from the Company's non-independent directors, since they recommend a majority of independent directors. This recommendation affected the level of support for the non-independent directors. The Company believes that its board of directors functions well; however, in response to shareholder requests, Belo Sun will look to supplement the board with the addition of another independent director. Belo Sun's board would like to express its gratitude to its shareholders for their high levels of participation and support. About the Company Belo Sun Mining Corp. is a Canadian-based mineral exploration and development company with a portfolio of gold-focused properties in Brazil. Belo Sun's primary focus is advancing and expanding its 100% owned Volta Grande Gold Project, located in Para State. Belo Sun trades on the TSX under the symbol "BSX". For more information about Belo Sun please visit www.belosun.com. Belo Sun Mining Corp. On behalf of the Board Peter Tagliamonte, President and Chief Executive Officer Caution regarding forward-looking information: This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the election of directors. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including risks inherent in the mining industry and risks described in the public disclosure of the Company which is available under the profile of the Company on SEDAR at www.sedar.com and on the Company's website at www.belosun.com. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.





Investor Relations
(416) 309-2137
[email protected]




Read more...

Ratios

vs
industry
vs
history
PE Ratio 84.35
BSX's PE Ratio is ranked lower than
88% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 27.53 vs. BSX: 84.35 )
Ranked among companies with meaningful PE Ratio only.
BSX' s PE Ratio Range Over the Past 10 Years
Min: 13.87  Med: 37.14 Max: 404.33
Current: 84.35
13.87
404.33
Forward PE Ratio 21.32
BSX's Forward PE Ratio is ranked higher than
59% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 21.79 vs. BSX: 21.32 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 84.35
BSX's PE Ratio without NRI is ranked lower than
89% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 27.51 vs. BSX: 84.35 )
Ranked among companies with meaningful PE Ratio without NRI only.
BSX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.87  Med: 37.14 Max: 404.33
Current: 84.35
13.87
404.33
Price-to-Owner-Earnings 49.82
BSX's Price-to-Owner-Earnings is ranked lower than
70% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 32.96 vs. BSX: 49.82 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BSX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.58  Med: 43.6 Max: 985.26
Current: 49.82
11.58
985.26
PB Ratio 5.26
BSX's PB Ratio is ranked lower than
71% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. BSX: 5.26 )
Ranked among companies with meaningful PB Ratio only.
BSX' s PB Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.45 Max: 5.3
Current: 5.26
0.59
5.3
PS Ratio 4.31
BSX's PS Ratio is ranked lower than
61% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. BSX: 4.31 )
Ranked among companies with meaningful PS Ratio only.
BSX' s PS Ratio Range Over the Past 10 Years
Min: 1.02  Med: 2.22 Max: 4.31
Current: 4.31
1.02
4.31
Price-to-Free-Cash-Flow 68.19
BSX's Price-to-Free-Cash-Flow is ranked lower than
81% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. BSX: 68.19 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BSX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.21  Med: 20.4 Max: 220
Current: 68.19
7.21
220
Price-to-Operating-Cash-Flow 38.13
BSX's Price-to-Operating-Cash-Flow is ranked lower than
77% of the 140 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. BSX: 38.13 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BSX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.75  Med: 15.77 Max: 62.72
Current: 38.13
5.75
62.72
EV-to-EBIT 87.09
BSX's EV-to-EBIT is ranked lower than
97% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. BSX: 87.09 )
Ranked among companies with meaningful EV-to-EBIT only.
BSX' s EV-to-EBIT Range Over the Past 10 Years
Min: -2577.3  Med: -3.95 Max: 25838
Current: 87.09
-2577.3
25838
EV-to-EBITDA 40.82
BSX's EV-to-EBITDA is ranked lower than
84% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. BSX: 40.82 )
Ranked among companies with meaningful EV-to-EBITDA only.
BSX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -680.1  Med: 8.45 Max: 242.5
Current: 40.82
-680.1
242.5
Current Ratio 0.87
BSX's Current Ratio is ranked lower than
89% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. BSX: 0.87 )
Ranked among companies with meaningful Current Ratio only.
BSX' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.56 Max: 7.77
Current: 0.87
0.52
7.77
Quick Ratio 0.59
BSX's Quick Ratio is ranked lower than
89% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. BSX: 0.59 )
Ranked among companies with meaningful Quick Ratio only.
BSX' s Quick Ratio Range Over the Past 10 Years
Min: 0.33  Med: 1.2 Max: 6.29
Current: 0.59
0.33
6.29
Days Inventory 143.75
BSX's Days Inventory is ranked lower than
58% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. BSX: 143.75 )
Ranked among companies with meaningful Days Inventory only.
BSX' s Days Inventory Range Over the Past 10 Years
Min: 113.61  Med: 133.18 Max: 164.78
Current: 143.75
113.61
164.78
Days Sales Outstanding 60.78
BSX's Days Sales Outstanding is ranked higher than
58% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. BSX: 60.78 )
Ranked among companies with meaningful Days Sales Outstanding only.
BSX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.51  Med: 61.98 Max: 66.79
Current: 60.78
58.51
66.79
Days Payable 54.85
BSX's Days Payable is ranked higher than
54% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. BSX: 54.85 )
Ranked among companies with meaningful Days Payable only.
BSX' s Days Payable Range Over the Past 10 Years
Min: 21.66  Med: 35.22 Max: 67.31
Current: 54.85
21.66
67.31

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.00
BSX's 3-Year Average Share Buyback Ratio is ranked higher than
70% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. BSX: -1.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BSX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.9  Med: -1 Max: 4.6
Current: -1
-25.9
4.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.80
BSX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
62% of the 129 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. BSX: 2.80 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BSX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.51  Med: 1.52 Max: 500
Current: 2.8
0.51
500
Price-to-Median-PS-Value 1.94
BSX's Price-to-Median-PS-Value is ranked lower than
86% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. BSX: 1.94 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BSX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.48  Med: 1.47 Max: 4.29
Current: 1.94
0.48
4.29
Price-to-Peter-Lynch-Fair-Value 1.52
BSX's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 57 Companies
in the Global Medical Devices industry.

( Industry Median: 1.61 vs. BSX: 1.52 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BSX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0  Med: 1.63 Max: 12.18
Current: 1.52
0
12.18
Earnings Yield (Greenblatt) % 1.16
BSX's Earnings Yield (Greenblatt) % is ranked lower than
58% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. BSX: 1.16 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BSX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.5  Med: 2.2 Max: 9.1
Current: 1.16
0.5
9.1
Forward Rate of Return (Yacktman) % 42.51
BSX's Forward Rate of Return (Yacktman) % is ranked higher than
97% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 8.85 vs. BSX: 42.51 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BSX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 3.1  Med: 6.9 Max: 42.51
Current: 42.51
3.1
42.51

More Statistics

Revenue (TTM) (Mil) $8,582
EPS (TTM) $ 0.32
Beta0.92
Short Percentage of Float1.34%
52-Week Range $19.67 - 26.97
Shares Outstanding (Mil)1,369.08

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 8,847 9,393 9,983
EPS ($) 1.25 1.40 1.56
EPS without NRI ($) 1.25 1.40 1.56
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.68%
Dividends per Share ($)
» More Articles for BSX

Headlines

Articles On GuruFocus.com
Boston Scientific Announces Positive Outcomes From Prospective Study Of Bronchial Thermoplasty May 24 2017 
Goldman Sachs Rates Health Care Stocks May 17 2017 
The Boston Scientific LOTUS™ Valve System Demonstrated Superior Efficacy to CoreValve® in Global May 16 2017 
Julian Robertson Buys Adobe and Sells Apple in 1st Quarter May 15 2017 
Boston Scientific Announces Positive European Registry Results For WATCHMAN™ Left Atrial Appendage May 12 2017 
New Data from PLATINUM Diversity Study Presented at SCAI 2017 Provide Important Insights Beyond Trad May 12 2017 
Boston Scientific S-ICD System Demonstrates Positive Clinical Outcomes in the Largest Prospective St May 11 2017 
Boston Scientific Announces Schedule of Presentations at EuroPCR 2017 May 10 2017 
Boston Scientific Receives U.S. FDA Approval For Resonate™ Family Of High-Voltage Devices May 09 2017 
Boston Scientific Announces Scheduled Presentations at Heart Rhythm Society 2017 May 03 2017 

More From Other Websites
Boston Scientific Announces Positive Outcomes From Prospective Study Of Bronchial Thermoplasty May 24 2017
[$$] Companies Are Winning the Battle Over Adjusted Earnings May 22 2017
Boston Scientific In Buy Zone, Gets Stock Rating Upgrade May 19 2017
Boston Scientific's Symetis Buyout Boosts Structural Heart May 18 2017
Boston Scientific Hits a 52-Week High on Solid Prospects May 17 2017
Boston Scientific to Participate in 2017 UBS Global Healthcare Conference May 17 2017
Blog Coverage: Boston Scientific Completes Symetis Acquisition; Views TAVI Portfolio Expansion... May 17 2017
Boston's Heart Valve Wins In Face-Off Trial With Rival Medtronic May 16 2017
The Boston Scientific LOTUS™ Valve System Demonstrated Superior Efficacy to CoreValve® in Global... May 16 2017
Boston Scientific Closes Symetis Acquisition May 16 2017
Boston Scientific Announces Positive European Registry Results For WATCHMAN™ Left Atrial Appendage... May 12 2017
New Data from PLATINUM Diversity Study Presented at SCAI 2017 Provide Important Insights Beyond... May 12 2017
Boston Scientific S-ICD System Demonstrates Positive Clinical Outcomes in the Largest Prospective... May 11 2017
Blog Coverage: FDA Approves Boston Scientific's Resonate Family of High-Voltage Devices May 10 2017
Boston Scientific Announces Schedule of Presentations at EuroPCR 2017 May 10 2017
India government panel rejects Boston Scientific plea on stent price caps May 09 2017
Behind Boston Scientific’s Recent Stock Performance May 09 2017
What Will Drive Boston Scientific’s Updated 2017 Guidance? May 09 2017
Inside Boston Scientific’s Acquisition of Symetis: The Must-Know Details May 09 2017
Cramer: These Sectors Look Bullish (Part III) May 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat